Clinical trial

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

NCT07443397

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-08-29

PhasePHASE3

Study timeline

Study start (actual)2025-08-29Date precision: day

Registry last updated2026-03-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Whole-Brain Radiotherapyunresolved

Interventions

AnlotinibDRUG

Whole-brain RadiotherapyRADIATION

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07443397 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.